HK1111702A1 - 含有非天然氨基酸及多肽的組合物及其所涉及的方法和用途 - Google Patents

含有非天然氨基酸及多肽的組合物及其所涉及的方法和用途

Info

Publication number
HK1111702A1
HK1111702A1 HK08102427.1A HK08102427A HK1111702A1 HK 1111702 A1 HK1111702 A1 HK 1111702A1 HK 08102427 A HK08102427 A HK 08102427A HK 1111702 A1 HK1111702 A1 HK 1111702A1
Authority
HK
Hong Kong
Prior art keywords
polypeptides
amino acids
compositions containing
natural amino
methods involving
Prior art date
Application number
HK08102427.1A
Other languages
English (en)
Chinese (zh)
Inventor
Zhenwei Miao
Junjie Liu
Thea Norman
Russell Driver
Original Assignee
Ambrx Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ambrx Inc filed Critical Ambrx Inc
Publication of HK1111702A1 publication Critical patent/HK1111702A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C225/00—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones
    • C07C225/02—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C225/04—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated
    • C07C225/08—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings
    • C07C225/10—Compounds containing amino groups and doubly—bound oxygen atoms bound to the same carbon skeleton, at least one of the doubly—bound oxygen atoms not being part of a —CHO group, e.g. amino ketones having amino groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being saturated and containing rings with doubly-bound oxygen atoms bound to carbon atoms not being part of rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
    • A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
    • C07C237/28—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton
    • C07C237/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a non-condensed six-membered aromatic ring of the carbon skeleton having the nitrogen atom of the carboxamide group bound to an acyclic carbon atom of a hydrocarbon radical substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/02—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups
    • C07C251/28—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton containing imino groups having nitrogen atoms of imino groups acylated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/54—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by singly-bound oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/32—Oximes
    • C07C251/50—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals
    • C07C251/60—Oximes having oxygen atoms of oxyimino groups bound to carbon atoms of substituted hydrocarbon radicals of hydrocarbon radicals substituted by carboxyl groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C251/00—Compounds containing nitrogen atoms doubly-bound to a carbon skeleton
    • C07C251/72—Hydrazones
    • C07C251/86—Hydrazones having doubly-bound carbon atoms of hydrazone groups bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/62—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton
    • C07C323/63—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atom of at least one of the thio groups bound to a carbon atom of a six-membered aromatic ring of the carbon skeleton the carbon skeleton being further substituted by nitrogen atoms, not being part of nitro or nitroso groups
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/38—Oxygen atoms in positions 2 and 3, e.g. isatin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/82—Benzo [b] furans; Hydrogenated benzo [b] furans with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/83—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88—Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87—Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/89—Benzo [c] furans; Hydrogenated benzo [c] furans with two oxygen atoms directly attached in positions 1 and 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/18—Radicals substituted by singly bound oxygen or sulfur atoms
    • C07D317/22—Radicals substituted by singly bound oxygen or sulfur atoms etherified
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/26—Radicals substituted by doubly bound oxygen or sulfur atoms or by two such atoms singly bound to the same carbon atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/28—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/10—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings
    • C07D317/14—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 not condensed with other rings with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D317/30—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/72—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 spiro-condensed with carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D333/72—Benzo[c]thiophenes; Hydrogenated benzo[c]thiophenes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/02—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length in solution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormones [GH] (Somatotropin)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C12P21/02—Preparation of peptides or proteins having a known sequence of two or more amino acids, e.g. glutathione
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
HK08102427.1A 2004-12-22 2008-03-04 含有非天然氨基酸及多肽的組合物及其所涉及的方法和用途 HK1111702A1 (zh)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US63841804P 2004-12-22 2004-12-22
US63919504P 2004-12-22 2004-12-22
US63852704P 2004-12-22 2004-12-22
US69621005P 2005-07-01 2005-07-01
US69630205P 2005-07-01 2005-07-01
US69606805P 2005-07-01 2005-07-01
PCT/US2005/046618 WO2006069246A2 (en) 2004-12-22 2005-12-21 Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides

Publications (1)

Publication Number Publication Date
HK1111702A1 true HK1111702A1 (zh) 2008-08-15

Family

ID=36602327

Family Applications (1)

Application Number Title Priority Date Filing Date
HK08102427.1A HK1111702A1 (zh) 2004-12-22 2008-03-04 含有非天然氨基酸及多肽的組合物及其所涉及的方法和用途

Country Status (16)

Country Link
US (20) US7385028B2 (US20060217532A1-20060928-C00019.png)
EP (2) EP2399893B1 (US20060217532A1-20060928-C00019.png)
JP (1) JP5425398B2 (US20060217532A1-20060928-C00019.png)
KR (1) KR101423769B1 (US20060217532A1-20060928-C00019.png)
CN (1) CN104803865A (US20060217532A1-20060928-C00019.png)
AU (2) AU2005319125A1 (US20060217532A1-20060928-C00019.png)
BR (1) BRPI0516385B1 (US20060217532A1-20060928-C00019.png)
CA (3) CA2927595C (US20060217532A1-20060928-C00019.png)
DK (2) DK1828224T3 (US20060217532A1-20060928-C00019.png)
GB (1) GB2438982A (US20060217532A1-20060928-C00019.png)
HK (1) HK1111702A1 (US20060217532A1-20060928-C00019.png)
IL (3) IL183346A (US20060217532A1-20060928-C00019.png)
MX (1) MX2007007590A (US20060217532A1-20060928-C00019.png)
NZ (1) NZ555308A (US20060217532A1-20060928-C00019.png)
SG (3) SG158186A1 (US20060217532A1-20060928-C00019.png)
WO (1) WO2006069246A2 (US20060217532A1-20060928-C00019.png)

Families Citing this family (112)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7138262B1 (en) 2000-08-18 2006-11-21 Shire Human Genetic Therapies, Inc. High mannose proteins and methods of making high mannose proteins
US20220144872A1 (en) * 2003-02-19 2022-05-12 Panion & Bf Biotech Inc. Pharmaceutical-Grade Ferric Organic Compounds, Uses Thereof and Methods of Making Same
US20050287639A1 (en) 2004-05-17 2005-12-29 California Institute Of Technology Methods of incorporating amino acid analogs into proteins
US20080076700A1 (en) * 2004-10-18 2008-03-27 Novo Nordisk A/S Method for the Preparation of Oxime, Thiazolidine, Dithiane, Dithiolane, or Hydrazone Linked Analogues of Growth Hormone
MX2007007590A (es) 2004-12-22 2007-12-10 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
JP5312799B2 (ja) * 2005-01-25 2013-10-09 ファイザー アイルランド ファーマシューティカルズ 収集精密ろ過における剪断保護剤
CA2630415A1 (en) * 2005-10-20 2007-04-26 The Scripps Research Institute Fc labeling for immunostaining and immunotargeting
CN101400646A (zh) 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
CN105384807A (zh) * 2005-12-14 2016-03-09 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
RS52459B (en) 2006-02-07 2013-02-28 Shire Human Genetic Therapies Inc. STABILIZED GLUCOCEREBROSIDASE COMPOSITIONS
SI1999259T1 (sl) 2006-03-03 2014-11-28 California Institute Of Technology Usmerjeno vključevanje amino kislin v molekule
US8580746B2 (en) * 2006-03-30 2013-11-12 Palatin Technologies, Inc. Amide linkage cyclic natriuretic peptide constructs
US8114844B2 (en) * 2006-03-30 2012-02-14 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptidomimetics
US7964181B2 (en) * 2006-03-30 2011-06-21 Palatin Technologies, Inc. Amino acid surrogates for peptidic constructs
AU2007292903B2 (en) 2006-09-08 2012-03-29 Ambrx, Inc. Modified human plasma polypeptide or Fc scaffolds and their uses
WO2008049034A1 (en) * 2006-10-17 2008-04-24 Zymera, Inc. System for assays of aminotranferase
US20100143326A1 (en) * 2007-01-03 2010-06-10 Novo Nordisk Healthcare A/G SUBCUTANEOUS ADMINISTRATION OF COAGULATION FACTOR VIIa-RELATED POLYPEPTIDES
KR101476472B1 (ko) 2007-03-30 2015-01-05 암브룩스, 인코포레이티드 변형된 ｆｇｆ-21 폴리펩티드 및 그 용도
CA2685596A1 (en) 2007-05-02 2008-11-13 Ambrx, Inc. Modified interferon beta polypeptides and their uses
WO2009036460A2 (en) * 2007-09-14 2009-03-19 Ambrx, Inc. Modified human apolipoprotein a-i polypeptides and their uses
NZ584825A (en) 2007-11-20 2013-03-28 Ambrx Inc Modified insulin polypeptides and their uses
AU2008335778B2 (en) 2007-12-11 2014-04-10 The Scripps Research Institute In vivo unnatural amino acid expression in the methylotrophic yeast Pichia pastoris
JP5514736B2 (ja) 2008-01-11 2014-06-04 セリナ・セラピユーテイツクス・インコーポレーテツド ポリオキサゾリン共重合体の多機能形態およびそれを含む薬物組成物
US8101706B2 (en) * 2008-01-11 2012-01-24 Serina Therapeutics, Inc. Multifunctional forms of polyoxazoline copolymers and drug compositions comprising the same
JP5702150B2 (ja) * 2008-02-08 2015-04-15 アンブルックス, インコーポレイテッドAmbrx, Inc. 修飾されているレプチンポリペプチドおよびそれらの使用
DE102008002209A1 (de) * 2008-06-04 2009-12-10 Evonik Degussa Gmbh Verfahren zur Aufreinigung von Erythropoietin
JP5680534B2 (ja) 2008-07-23 2015-03-04 イーライ リリー アンド カンパニー 修飾されているウシｇ−ｃｓｆポリペプチドおよびそれらの使用
CN102307905B (zh) * 2008-12-10 2015-11-25 斯克利普斯研究院 利用化学反应性非天然氨基酸产生载体-肽偶联物
US20090197339A1 (en) * 2008-12-10 2009-08-06 The Scripps Research Institute In vivo unnatural amino acid expression in the methylotrophic yeast pichia pastoris
WO2010096394A2 (en) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Aldehyde-tagged protein-based drug carriers and methods of use
EP2406276A4 (en) * 2009-03-13 2012-12-05 Aerovance Inc METHOD OF RENATURING RECOMBINANT PROTEINS
DE102009015347A1 (de) * 2009-03-27 2010-09-30 Man Nutzfahrzeuge Aktiengesellschaft Dieselkraftstoff auf Ethanol-Basis
FR2947269B1 (fr) 2009-06-29 2013-01-18 Sanofi Aventis Nouveaux composes anticancereux
ES2668079T3 (es) 2009-07-28 2018-05-16 Shire Human Genetic Therapies Composiciones y métodos para tratar la enfermedad de Gaucher
FR2949469A1 (fr) 2009-08-25 2011-03-04 Sanofi Aventis Derives anticancereux, leur preparation et leur application en therapeutique
AR078471A1 (es) 2009-10-02 2011-11-09 Sanofi Aventis COMPUESTOS MAITANSINOIDES Y EL USO DE ESTOS PARA PREPARAR CONJUGADOS CON UN ANTICUERPO LOS CUALES SE UTILIZAN COMO AGENTES ANTICANCERIGENOS Y EL PROCEDIMIENTO DE PREPARACIoN DE ESTOS CONJUGADOS
WO2011044255A1 (en) * 2009-10-06 2011-04-14 The Ohio State University Pyrrolysine analogs
CN107674121A (zh) 2009-12-21 2018-02-09 Ambrx 公司 经过修饰的牛促生长素多肽和其用途
CN104017063A (zh) 2009-12-21 2014-09-03 Ambrx公司 经过修饰的猪促生长素多肽和其用途
US20110160143A1 (en) * 2009-12-28 2011-06-30 Perricone Nicholas V Topical Acyl Glutathione Psoriasis Compositions
JP6210685B2 (ja) 2010-01-27 2017-10-11 マサチューセッツ インスティテュート オブ テクノロジー 標的化された広域スペクトルのインフルエンザ中和のための操作されたポリペプチド剤
JP5794558B2 (ja) * 2010-03-24 2015-10-14 国立研究開発法人産業技術総合研究所 改変された致死遺伝子及び該遺伝子を含むベクター
FR2963007B1 (fr) 2010-07-26 2013-04-05 Sanofi Aventis Derives anticancereux, leur preparation et leur application therapeutique
US9567386B2 (en) 2010-08-17 2017-02-14 Ambrx, Inc. Therapeutic uses of modified relaxin polypeptides
MX346786B (es) 2010-08-17 2017-03-31 Ambrx Inc Polipeptidos de relaxina modificados y sus usos.
AR083006A1 (es) 2010-09-23 2013-01-23 Lilly Co Eli Formulaciones para el factor estimulante de colonias de granulocitos (g-csf) bovino y variantes de las mismas
BR112013015898A2 (pt) 2010-12-22 2018-06-26 Baxter International Inc. derivado de ácido graxo solúvel em água, e, métodos para preparar um derivado de ácido graxo e uma proteína terapêutica conjugada.
AU2012205301B2 (en) 2011-01-14 2017-01-05 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and method of use thereof
JP2013199466A (ja) * 2012-02-24 2013-10-03 Fujifilm Corp リコピン含有組成物
EP2819702A4 (en) * 2012-02-29 2015-05-20 Ambrx Inc NOVEL PRODRUGS WITH MOLECULE COMPOSITIONS AND ITS USES
CA2865614A1 (en) 2012-03-02 2013-09-06 Shire Human Genetic Therapies, Inc. Compositions and methods for treating type iii gaucher disease
CA2871160C (en) 2012-05-10 2023-03-14 Massachusetts Institute Of Technology Agents for influenza neutralization
AU2013270686B2 (en) * 2012-06-07 2016-11-10 Ambrx, Inc. Prostate-specific membrane antigen antibody drug conjugates
AU2013270684B2 (en) 2012-06-08 2018-04-19 Sutro Biopharma, Inc. Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use
EP2861262B1 (en) * 2012-06-19 2018-11-28 Ambrx, Inc. Anti-cd70 antibody drug conjugates
GB201211353D0 (en) 2012-06-26 2012-08-08 Cm Online Ltd Interactive video
DK2863955T3 (en) 2012-06-26 2017-01-23 Sutro Biopharma Inc MODIFIED FC PROTEINS, INCLUDING LOCATION-SPECIFIC NON-NATURAL AMINO ACID RESIDUES, CONJUGATES THEREOF, METHODS OF PRODUCING ITS AND PROCEDURES FOR USE THEREOF
EP4074728A1 (en) 2012-08-31 2022-10-19 Sutro Biopharma, Inc. Modified peptides comprising an azido group
CN103933575B (zh) 2013-01-23 2017-09-29 上海新理念生物医药科技有限公司 一种三齿型连接子及其应用
JP6574754B2 (ja) 2013-03-19 2019-09-11 ベイジン シェノゲン ファーマ グループ リミテッド エストロゲン受容体関連疾患を処置するための抗体及び方法
ES2865473T3 (es) 2013-07-10 2021-10-15 Sutro Biopharma Inc Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso
KR102637699B1 (ko) 2014-10-24 2024-02-19 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
WO2016069726A1 (en) * 2014-10-28 2016-05-06 President And Fellows Of Harvard College Methods of making polypeptides with non-standard amino acids using genomically recoded organisms
WO2016073894A1 (en) 2014-11-07 2016-05-12 Eleven Biotherapeutics, Inc. Therapeutic agents with increased ocular retention
EA039794B1 (ru) 2014-12-04 2022-03-15 Селджин Корпорейшн Конъюгаты биомолекул
CN107615069B (zh) * 2015-03-31 2021-04-20 荣研化学株式会社 血红素蛋白保存液和血红素蛋白稳定化方法
KR20240046641A (ko) 2015-04-17 2024-04-09 알파인 이뮨 사이언시즈, 인코포레이티드 조율가능한 친화성을 갖는 면역조절 단백질
AU2015242213A1 (en) 2015-07-12 2018-03-08 Hangzhou Dac Biotech Co., Ltd Bridge linkers for conjugation of cell-binding molecules
US9839687B2 (en) 2015-07-15 2017-12-12 Suzhou M-Conj Biotech Co., Ltd. Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
EP3407917A1 (en) 2016-01-27 2018-12-05 Sutro Biopharma, Inc. Anti-cd74 antibody conjugates, compositions comprising anti-cd74 antibody conjugates and methods of using anti-cd74 antibody conjugates
US11884612B2 (en) 2016-03-16 2024-01-30 The Regents Of The University Of California Covalent peptide binders
AU2017257504A1 (en) 2016-04-26 2018-10-25 R.P. Scherer Technologies, Llc Antibody conjugates and methods of making and using the same
KR20220147720A (ko) 2016-11-14 2022-11-03 항저우 디에이씨 바이오테크 씨오, 엘티디 결합 링커, 그러한 결합 링커를 함유하는 세포 결합 분자-약물 결합체, 링커를 갖는 그러한 결합체의 제조 및 사용
SG11201907209QA (en) 2017-02-08 2019-09-27 Bristol Myers Squibb Co Modified relaxin polypeptides comprising a pharmacokinetic enhancer and uses thereof
AU2018225163A1 (en) 2017-02-22 2019-09-19 Bioincept, Llc Peptides and methods of treating dystrophy-related disorders using the same
WO2018200381A1 (en) 2017-04-25 2018-11-01 Temple Otorongo Llc Pharmaceutical composition comprising tryptophan and phyllokinin derivative for use in treating psychiatric and psychological conditions
BR112020000115A2 (pt) * 2017-07-05 2020-07-07 Biocells (Beijing) Biotech Co., Ltd. sais farmaceuticamente aceitáveis de polipeptídeos e uso dos mesmos
WO2019018447A2 (en) 2017-07-17 2019-01-24 Bioincept, Llc PEPTIDES AND METHODS OF TRANSPLANTATION AND RESTORATION OF ORGAN FUNCTION
EP3761972A4 (en) * 2018-03-08 2021-12-15 The Regents of the University of California BIOREACTIVE COMPOSITIONS AND METHOD OF USING THEREOF
CN108538399A (zh) * 2018-03-22 2018-09-14 复旦大学 一种磁共振肝癌疗效评估方法和系统
WO2019185706A1 (en) 2018-03-28 2019-10-03 Ascendis Pharma A/S Conjugates
AU2019246389A1 (en) 2018-03-28 2020-08-27 Ascendis Pharma Oncology Division A/S IL-2 conjugates
CN110760306B (zh) * 2018-07-27 2021-11-23 Tcl科技集团股份有限公司 一种量子点的提纯方法
MX2021002301A (es) 2018-08-28 2021-04-28 Ambrx Inc Bioconjugados de anticuerpo-foliato anti-cd3 y sus usos.
JP2021536263A (ja) * 2018-09-07 2021-12-27 メディミューン，エルエルシー 細胞選択の方法
PL3849614T3 (pl) 2018-09-11 2024-04-22 Ambrx, Inc. Koniugaty polipeptydu interleukiny-2 i ich zastosowania
CN113366015A (zh) 2018-10-19 2021-09-07 Ambrx公司 白细胞介素-10多肽缀合物、其二聚体及其用途
EP3923991A1 (en) 2019-02-12 2021-12-22 Ambrx, Inc. Compositions containing, methods and uses of antibody-tlr agonist conjugates
CA3130693A1 (en) 2019-02-19 2020-08-27 Ultima Genomics, Inc. Linkers and methods for optical detection and sequencing
KR20220029725A (ko) 2019-06-29 2022-03-08 항저우 디에이씨 바이오테크 씨오, 엘티디 세포-결합 분자-튜불리신 유도체 접합체 및 이의 제조 방법
WO2021102624A1 (en) * 2019-11-25 2021-06-03 Hangzhou Branch Of Technical Institute Of Physics And Chemistry, Chinese Academy Of Sciences Covalent protein drugs developed via proximity-enabled reactive therapeutics (perx)
US11807851B1 (en) 2020-02-18 2023-11-07 Ultima Genomics, Inc. Modified polynucleotides and uses thereof
WO2021173889A1 (en) 2020-02-26 2021-09-02 Ambrx, Inc. Uses of anti-cd3 antibody folate bioconjugates
AU2021233909A1 (en) 2020-03-11 2022-09-29 Ambrx, Inc. Interleukin-2 polypeptide conjugates and methods of use thereof
JPWO2021215428A1 (US20060217532A1-20060928-C00019.png) * 2020-04-22 2021-10-28
CN112028987B (zh) * 2020-06-01 2021-07-30 广东圣赛生物科技有限公司 一种结合免疫抑制分子pd-l1的蛋白药物
EP4161956A1 (en) 2020-06-03 2023-04-12 Ascendis Pharma Oncology Division A/S Il-2 sequences and uses thereof
EP4199969A1 (en) * 2020-08-18 2023-06-28 Ultima Genomics, Inc. Reagents for labeling biomolecules
KR20230073200A (ko) 2020-08-20 2023-05-25 암브룩스, 인코포레이티드 항체-tlr 작용제 접합체, 그 방법 및 용도
WO2022194078A1 (zh) * 2021-03-15 2022-09-22 北京大学 用于靶分子修饰的缀合物及其制备方法
JP2024512775A (ja) 2021-04-03 2024-03-19 アンブルックス，インコーポレイテッド 抗ｈｅｒ２抗体薬物コンジュゲート及びその使用
EP4330214A2 (en) * 2021-04-28 2024-03-06 The Regents of the University of California Bioreactive proteins containing unnatural amino acids
US20230201365A1 (en) 2021-07-09 2023-06-29 Bright Peak Therapeutics Ag Modified cd20 antibodies and uses thereof
KR20240041379A (ko) 2021-07-09 2024-03-29 브라이트 피크 테라퓨틱스 아게 Il-2에 접합된 체크포인트 억제제 및 이의 용도
CA3222359A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Ag Conjugates of checkpoint inhibitors with il-2, and uses thereof
US20230183331A1 (en) 2021-07-09 2023-06-15 Bright Peak Therapeutics Ag Modified tnf-alpha antibodies and uses thereof
WO2023281481A1 (en) 2021-07-09 2023-01-12 Bright Peak Therapeutics Antibody conjugates and manufacture thereof
WO2023161857A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Bifunctional cytokine compositions
WO2023161854A1 (en) 2022-02-23 2023-08-31 Bright Peak Therapeutics Ag Immune antigen specific il-18 immunocytokines and uses thereof
WO2024077277A1 (en) 2022-10-07 2024-04-11 Ambrx, Inc. Drug linkers and antibody conjugates thereof
KR102524528B1 (ko) * 2022-11-24 2023-04-21 주식회사 리얼이펙트 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드의 제조방법
KR102526689B1 (ko) * 2022-11-24 2023-04-28 주식회사 리얼이펙트 양친매성 항균펩타이드인 알루미늄 팔미토일다이펩타이드-4를 포함하는 액정수화 화장료 조성물

Family Cites Families (187)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US644281A (en) * 1899-12-01 1900-02-27 Samuel Crump Process of drying and varnishing prints.
US3849576A (en) * 1964-01-29 1974-11-19 Oreal Process and cosmetic compositions for the treatment of skin and scalp
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
GB1366554A (en) * 1972-03-06 1974-09-11 Science Union & Cie Phenylalanine derivatives and a process for their preparation
US4272432A (en) * 1974-11-13 1981-06-09 American Home Products Corporation Claudogenic-interceptive nonapeptide
ZA783356B (en) * 1977-07-21 1979-06-27 Merrell Toraude & Co A-halomethyl amino acid derivatives
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
US4289872A (en) 1979-04-06 1981-09-15 Allied Corporation Macromolecular highly branched homogeneous compound based on lysine units
ZA811368B (en) 1980-03-24 1982-04-28 Genentech Inc Bacterial polypedtide expression employing tryptophan promoter-operator
EP0052322B1 (de) 1980-11-10 1985-03-27 Gersonde, Klaus, Prof. Dr. Verfahren zur Herstellung von Lipid-Vesikeln durch Ultraschallbehandlung, Anwendung des Verfahrens und Vorrichtung zur Durchführung des Verfahrens
DE3043159C2 (de) * 1980-11-15 1982-12-09 Degussa Ag, 6000 Frankfurt Cyclische Acetale des Glutaminsäure-γ-semialdehyds, Verfahren zu deren Herstellung und ihre Verwendung
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
FR2504010B1 (fr) 1981-04-15 1985-10-25 Sanofi Sa Medicaments anticancereux contenant la chaine a de la ricine associee a un anticorps antimelanome et procede pour leur preparation
US4551433A (en) 1981-05-18 1985-11-05 Genentech, Inc. Microbial hybrid promoters
JPS57206622A (en) 1981-06-10 1982-12-18 Ajinomoto Co Inc Blood substitute
US4485045A (en) 1981-07-06 1984-11-27 Research Corporation Synthetic phosphatidyl cholines useful in forming liposomes
NZ201705A (en) 1981-08-31 1986-03-14 Genentech Inc Recombinant dna method for production of hepatitis b surface antigen in yeast
JPS58118008A (ja) 1982-01-06 1983-07-13 Nec Corp デ−タ処理装置
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
DE3218121A1 (de) 1982-05-14 1983-11-17 Leskovar, Peter, Dr.-Ing., 8000 München Arzneimittel zur tumorbehandlung
EP0102324A3 (de) 1982-07-29 1984-11-07 Ciba-Geigy Ag Lipide und Tenside in wässriger Phase
US4511502A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4512922A (en) 1982-12-22 1985-04-23 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4511503A (en) 1982-12-22 1985-04-16 Genentech, Inc. Purification and activity assurance of precipitated heterologous proteins
US4820352A (en) 1983-01-10 1989-04-11 Bausch & Lomb Incorporated Cleaning and conditioning solutions for contact lenses and methods of use
US5089398A (en) 1983-02-22 1992-02-18 Chiron Corporation Enhanced yeast transcription employing hybrid GAPDH promoter region constructs
CA1341302C (en) 1983-02-22 2001-10-09 Rae Lyn Burke Yeast expression systems with vectors having gapdh or pyk promoters and synthesis of foreign protein
US4876197A (en) 1983-02-22 1989-10-24 Chiron Corporation Eukaryotic regulatable transcription
JPS59166086A (ja) 1983-03-09 1984-09-19 Teruhiko Beppu 新規な発現型プラスミドとそれらを用いて仔牛プロキモシン遺伝子を大腸菌内で発現させる方法
EP0127839B1 (en) 1983-05-27 1992-07-15 THE TEXAS A&M UNIVERSITY SYSTEM Method for producing a recombinant baculovirus expression vector
US4544545A (en) 1983-06-20 1985-10-01 Trustees University Of Massachusetts Liposomes containing modified cholesterol for organ targeting
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
US4689406A (en) 1983-08-10 1987-08-25 Amgen Enhancement of microbial expression of polypeptides
ATE59966T1 (de) 1983-09-26 1991-02-15 Ehrenfeld Udo Mittel und erzeugnis fuer die diagnose und therapie von tumoren sowie zur behandlung von schwaechen der zelligen und humoralen immunabwehr.
US4615885A (en) 1983-11-01 1986-10-07 Terumo Kabushiki Kaisha Pharmaceutical composition containing urokinase
ZA848495B (en) 1984-01-31 1985-09-25 Idaho Res Found Production of polypeptides in insect cells
EP0480480A3 (en) 1984-05-11 1992-06-10 Chiron Corporation Enhanced yeast transcription employing hybrid promoter region constructs
US4880734A (en) 1984-05-11 1989-11-14 Chiron Corporation Eukaryotic regulatable transcription
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
US4738921A (en) 1984-09-27 1988-04-19 Eli Lilly And Company Derivative of the tryptophan operon for expression of fused gene products
US4659839A (en) 1984-10-10 1987-04-21 Mallinckrodt, Inc. Coupling agents for radiolabeled antibody fragments
US4837148A (en) 1984-10-30 1989-06-06 Phillips Petroleum Company Autonomous replication sequences for yeast strains of the genus pichia
DE3680924D1 (de) 1985-01-14 1991-09-26 Neorx Corp Metall-radionuklid markiertes protein fuer diagnose und therapie.
JPS61243018A (ja) * 1985-04-18 1986-10-29 Taisho Pharmaceut Co Ltd 真菌症治療剤
EP0206448B1 (en) 1985-06-19 1990-11-14 Ajinomoto Co., Inc. Hemoglobin combined with a poly(alkylene oxide)
US4680338A (en) 1985-10-17 1987-07-14 Immunomedics, Inc. Bifunctional linker
US4699784A (en) 1986-02-25 1987-10-13 Center For Molecular Medicine & Immunology Tumoricidal methotrexate-antibody conjugate
GB8610600D0 (en) 1986-04-30 1986-06-04 Novo Industri As Transformation of trichoderma
US5186933A (en) 1986-12-30 1993-02-16 Baylor College Of Medicine Synthesis and immunogenicity of rotavirus genes using a baculovirus expression system
EP0349594A4 (en) 1987-03-16 1990-09-26 American Biogenetic Sciences, Inc. Recombinant baculovirus occlusion bodies in vaccines and biological insecticides
ATE103333T1 (de) 1987-03-23 1994-04-15 Zymogenetics Inc Hohe proteinsyntheserate in hefe.
US5229490A (en) 1987-05-06 1993-07-20 The Rockefeller University Multiple antigen peptide system
CA1317244C (en) 1987-07-24 1993-05-04 Ernest Seigo Kawasaki Production of biologically active forms of csf using a baculovirus (acnpv)-insect cell expression system
AU2136788A (en) 1987-07-24 1989-03-01 Cetus Corporation Production of ricin toxins in a baculovirus-insect cell expression system
US5080891A (en) 1987-08-03 1992-01-14 Ddi Pharmaceuticals, Inc. Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols
US4929555A (en) 1987-10-19 1990-05-29 Phillips Petroleum Company Pichia transformation
ES2012739T5 (es) 1987-11-18 2001-12-01 Chiron Corp Diagnosticos para nanbv.
CA1340772C (en) 1987-12-30 1999-09-28 Patricia Tekamp-Olson Expression and secretion of heterologous protiens in yeast employing truncated alpha-factor leader sequences
EP0355147B1 (en) 1988-01-13 1995-04-19 Institut Pasteur Dna probe specific for pathogenic listeria
CA1324969C (en) 1988-05-06 1993-12-07 Jeffrey R. Shuster High level expression of proteins in yeast
US5674706A (en) 1988-05-06 1997-10-07 Chiron Corporation High level expression of proteins in yeast
FR2631974B1 (fr) 1988-05-31 1992-12-11 Agronomique Inst Nat Rech Baculovirus modifie, son procede de preparation et son application en tant que vecteur d'expression de genes
AU4197389A (en) 1988-08-05 1990-03-05 Mount Sinai School Of Medicine Of The City University Of New York, The In vivo infection of live insects with a recombinant baculovirus
GB8819453D0 (en) 1988-08-16 1988-09-21 Roy P Production of bluetongue virus non-structural proteins using baculovirus expression vector
NZ230425A (en) 1988-09-02 1992-07-28 Molecular Eng Ass Production of paramyxovirus fusion (f) protein using recombinant baculovirus expression vector
AU649217B2 (en) 1988-11-18 1994-05-19 Regents Of The University Of California, The Method for site-specifically incorporating unnatural amino acids into proteins
WO1990010078A1 (en) 1989-02-23 1990-09-07 University Of Ottawa Improved baculovirus expression system capable of producing foreign gene proteins at high levels
CA2045614C (en) 1989-02-24 1997-09-30 James W. Bacus Method and apparatus for determining a proliferation index of a cell sample
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
DE69033192T3 (de) 1989-04-19 2004-05-19 Enzon, Inc. Aktive karbonate von polyalkylenoxyden zur modifizierung von polypeptiden
JPH04501065A (ja) 1989-05-17 1992-02-27 ユニバーシティ オブ ジョージア リサーチ ファウンデーション インコーポレイテッド 改良されたバキュロウイルス発現ベクター
FR2649120B1 (fr) 1989-06-30 1994-01-28 Cayla Nouvelle souche et ses mutants de champignons filamenteux, procede de production de proteines recombinantes a l'aide de ladite souche et souches et proteines obtenues selon ce procede
US5312808A (en) 1989-11-22 1994-05-17 Enzon, Inc. Fractionation of polyalkylene oxide-conjugated hemoglobin solutions
US5364840A (en) * 1989-12-05 1994-11-15 Vical, Inc. Synthetic calcitonin peptides
US5219564A (en) 1990-07-06 1993-06-15 Enzon, Inc. Poly(alkylene oxide) amino acid copolymers and drug carriers and charged copolymers based thereon
CA2018801C (en) * 1990-06-12 2000-08-22 Pierre Louis Beaulieu Antiherpes peptide derivatives having a 1,4-dioxo c n-terminus
FR2664905B1 (fr) 1990-07-18 1994-08-12 Agronomique Inst Nat Rech Baculovirus modifie, son procede d'obtention, et vecteurs d'expression obtenus a partir dudit baculovirus.
WO1992001800A1 (en) 1990-07-20 1992-02-06 Chiron Corporation Method for integrative transformation of yeast using dispersed repetitive elements
FR2665923B1 (fr) 1990-08-14 1993-01-22 Arbona Jean Unite de soins modulaire.
WO1992004363A1 (en) 1990-09-04 1992-03-19 The Salk Institute Biotechnology/Industrial Associates, Inc. Production of insulin-like growth factor-1 in methylotrophic yeast cells
IL99537A (en) * 1990-09-27 1995-11-27 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical preparations containing them
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US5231178A (en) 1991-01-16 1993-07-27 The Salk Institute Biotechnology/Industrial Associates, Inc. Method for the purification of intact, correctly-folded insulin-like growth factor-1
WO1992016619A1 (en) 1991-03-19 1992-10-01 Us Army Expression of influenza nucleoprotein antigens in baculovirus
US6126944A (en) 1991-04-26 2000-10-03 The United States Of America As Represented By The Department Of Health And Human Services Baculovirus expression vectors and recombinant antigens for detecting type-specific antibodies to herpes simplex virus
US5281698A (en) 1991-07-23 1994-01-25 Cetus Oncology Corporation Preparation of an activated polymer ester for protein conjugation
US5290686A (en) 1991-07-31 1994-03-01 The United States Of America As Represented By The Department Of Health And Human Services Expression of influenza a M2 protein in baculovirus
IT1260468B (it) 1992-01-29 1996-04-09 Metodo per mantenere l'attivita' di enzimi proteolitici modificati con polietilenglicole
CA2118130A1 (en) 1992-04-14 1993-10-28 Jean M. J. Frechet Dendritic based macromolecules and method of production
US5516657A (en) 1992-05-11 1996-05-14 Cambridge Biotech Corporation Baculovirus vectors for expression of secretory and membrane-bound proteins
AU5006993A (en) 1992-08-21 1994-03-15 Enzon, Inc. Novel attachment of polyalkylene oxides to bio-effecting substances
CA2110543A1 (en) * 1992-12-09 1994-06-10 David E. Wright Peg hydrazone and peg oxime linkage forming reagents and protein derivatives thereof
NZ250375A (en) 1992-12-09 1995-07-26 Ortho Pharma Corp Peg hydrazone and peg oxime linkage forming reagents and protein derivatives
AU6029594A (en) 1993-01-15 1994-08-15 Enzon, Inc. Factor viii - polymeric conjugates
US5349001A (en) 1993-01-19 1994-09-20 Enzon, Inc. Cyclic imide thione activated polyalkylene oxides
US5321095A (en) 1993-02-02 1994-06-14 Enzon, Inc. Azlactone activated polyalkylene oxides
US5464820A (en) * 1993-06-22 1995-11-07 The University Hospital Specific inhibitors of tissue kallikrein
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
DE4335555A1 (de) * 1993-10-19 1995-04-20 Basf Ag Oximether und diese enthaltende Copolymerisate
US5643575A (en) 1993-10-27 1997-07-01 Enzon, Inc. Non-antigenic branched polymer conjugates
US5605792A (en) 1993-11-04 1997-02-25 The Ohio State University Research Foundation Infectious bursal disease virus VP2 fusion protein expressed by baculovirus, use as diagnostic
US5446090A (en) 1993-11-12 1995-08-29 Shearwater Polymers, Inc. Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and molecules
FR2715664B1 (fr) 1994-01-31 1996-04-12 Proteine Performance Sa Baculovirus recombinant et son utilisation pour la production d'anticorps monoclonaux.
JP3090586B2 (ja) 1994-03-15 2000-09-25 片倉工業株式会社 システインプロテアーゼ遺伝子欠損バキュロウイルスおよびその製造法並びにこれを利用する有用タンパク質の製造法
US6403375B1 (en) 1994-08-24 2002-06-11 Boyce Thompson Institute For Plant Research, Inc. Establishment of Trichoplusia ni cell lines in serum-free medium for recombinant protein and baculovirus production
US5650234A (en) 1994-09-09 1997-07-22 Surface Engineering Technologies, Division Of Innerdyne, Inc. Electrophilic polyethylene oxides for the modification of polysaccharides, polypeptides (proteins) and surfaces
US5871986A (en) 1994-09-23 1999-02-16 The General Hospital Corporation Use of a baculovirus to express and exogenous gene in a mammalian cell
US5824784A (en) 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
WO1996041813A2 (en) 1994-11-09 1996-12-27 Offord Robin E Functionalized polymers for site-specific attachment
IL116085A (en) 1994-12-16 1999-12-31 Ortho Pharma Corp Spray dried erythropoietin
US5932462A (en) 1995-01-10 1999-08-03 Shearwater Polymers, Inc. Multiarmed, monofunctional, polymer for coupling to molecules and surfaces
WO1996025496A1 (en) 1995-02-17 1996-08-22 Instituut Voor Dierhouderij En Diergezondheid (Id-Dlo) PRODUCTION OF BIOLOGICALLY ACTIVE RECOMBINANT BOVINE FOLLICLE STIMULATING HORMONE (REC bFSH) IN THE BACULOVIRUS EXPRESSION SYSTEM
FR2732035B1 (fr) 1995-03-23 1997-05-30 Agronomique Inst Nat Rech Procede de regulation de l'expression d'un gene dans un baculovirus, par un site de fixation d'un recepteur de l'acide retinoique, et vecteur pour la mise en oeuvre du dit procede
US6184344B1 (en) 1995-05-04 2001-02-06 The Scripps Research Institute Synthesis of proteins by native chemical ligation
NZ308772A (en) 1995-05-17 1999-04-29 Du Pont Recombinant baculovirus insecticides
JPH09157578A (ja) * 1995-12-08 1997-06-17 Daikin Ind Ltd 含フッ素塗料用材料およびそれを用いた被覆方法
US5672662A (en) 1995-07-07 1997-09-30 Shearwater Polymers, Inc. Poly(ethylene glycol) and related polymers monosubstituted with propionic or butanoic acids and functional derivatives thereof for biotechnical applications
US5861279A (en) 1996-01-17 1999-01-19 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
WO1997026332A1 (en) 1996-01-17 1997-07-24 Schering Corporation Baculovirus expression system for human interleukin 5 receptor and method of screening for interleukin 5 antagonists
US5876916A (en) * 1996-03-18 1999-03-02 Case Western Reserve University Pyruvate compounds and methods for use thereof
IL128229A0 (en) * 1996-08-02 1999-11-30 Ortho Mcneil Pharm Inc Polypeptides having a single covalently bound n-terminal water-soluble polymer
DE69739319D1 (de) 1996-12-13 2009-04-30 Novartis Vaccines & Diagnostic Verfahren zur Expression von PDGF oder IGR Proteinen in Hefe
GB9703406D0 (en) 1997-02-19 1997-04-09 Chiron Spa Expression of heterologous proteins
US6399337B1 (en) * 1997-06-06 2002-06-04 The Governors Of The University Of Alberta α1,3-fucosyltransferase
US5965393A (en) 1997-07-01 1999-10-12 National Institute Of Immunology Method for enhancing foreign gene expression in baculovirus expression vector system
EP1881005B1 (en) * 1997-07-14 2013-04-03 Bolder Biotechnology, Inc. Derivatives of G-CSF and related proteins
GB9715660D0 (en) 1997-07-25 1997-10-01 Zeneca Ltd Proteins
US6492421B1 (en) 1997-07-31 2002-12-10 Athena Neurosciences, Inc. Substituted phenylalanine type compounds which inhibit leukocyte adhesion mediated by VLA-4
EP1003889A1 (en) 1997-08-05 2000-05-31 Chiron Corporation NOVEL $i(PICHIA PASTORIS) GENE SEQUENCES AND METHODS FOR THEIR USE
DE19735593C2 (de) 1997-08-15 1999-08-26 Hepavec Ag Fuer Gentherapie Hüllprotein-modifizierter Baculovirus-Vektor für die Gentherapie
US6090584A (en) 1997-08-21 2000-07-18 University Technologies International Inc. Baculovirus artificial chromosomes and methods of use
US6455550B1 (en) 1997-08-22 2002-09-24 Hoffmann-La Roche Inc. N-alkanoylphenylalanine derivatives
ATE462004T1 (de) 1997-09-16 2010-04-15 Centocor Inc Methoden zur kompletten chemischen synthese und zusammensetzung von genen und genomen
US6449281B1 (en) 1997-09-30 2002-09-10 Intel Corporation Interface control of communication between a control processor and a digital signal processor
JPH11140076A (ja) * 1997-11-04 1999-05-25 Dai Ichi Pure Chem Co Ltd Ｎ−アシル−α−アミノアジピン酸−γ−セミアルデヒドエチレンアセタール
EP0924298A1 (en) 1997-12-18 1999-06-23 Stichting Instituut voor Dierhouderij en Diergezondheid (ID-DLO) Protein expression in baculovirus vector expression systems
WO1999045130A1 (en) 1998-03-04 1999-09-10 Onyx Pharmaceuticals, Inc. Baculovirus expression system and method for high throughput expression of genetic material
DE69921102T2 (de) 1998-03-05 2006-02-02 Chiron Corp., Emeryville Verfahren zur verbesserung der serum-halbwertszeit von biologisch aktiven molekülen
PT1062201E (pt) * 1998-03-11 2005-02-28 Searle & Co Derivados halogenados de amidino-aminoacidos uteis como inibidores da sintase do acido nitrico
KR100264953B1 (ko) 1998-04-03 2001-03-02 박현우 재조합 베큘로바이러스, 이의 제조방법 및 이를 포함하는 미생물 살충제
US6168932B1 (en) 1998-07-13 2001-01-02 Parker Hughes Institute Recombinant DTctGMCSF fusion toxin in a baculovirus expression vector system
US6245528B1 (en) 1998-07-28 2001-06-12 Academia Sinica Latent baculovirus expression system
US6368825B1 (en) 1998-08-10 2002-04-09 Academia Sinica Baculovirus containing minimal CMV promoter
AU6059699A (en) * 1998-09-23 2000-04-10 Regents Of The University Of California, The Synthetic peptides, conjugation reagents and methods
WO2000020032A1 (en) 1998-10-06 2000-04-13 Trustees Of Dartmouth College RECOMBINANT CAT ALLERGEN, Fel dI, EXPRESSED IN BACULOVIRUS FOR DIAGNOSIS AND TREATMENT OF CAT ALLERGY
CA2365668C (en) 1999-03-17 2014-05-20 The Board Of Trustees Of The Leland Stanford Junior University In vitro macromolecule biosynthesis methods using exogenous amino acids and a novel atp regeneration system
US6994986B2 (en) * 1999-03-17 2006-02-07 The Board Of Trustees Of The Leland Stanford University In vitro synthesis of polypeptides by optimizing amino acid metabolism
US6342216B1 (en) 1999-03-17 2002-01-29 The Board Of Regents, The University Of Texas System Therapy of cancer by insect cells containing recombinant baculovirus encoding genes
US6337191B1 (en) 1999-03-22 2002-01-08 The Board Of Trustees Of The Leland Stanford Junior University Vitro protein synthesis using glycolytic intermediates as an energy source
US6312725B1 (en) 1999-04-16 2001-11-06 Cohesion Technologies, Inc. Rapid gelling biocompatible polymer composition
US6261805B1 (en) 1999-07-15 2001-07-17 Boyce Thompson Institute For Plant Research, Inc. Sialyiation of N-linked glycoproteins in the baculovirus expression vector system
AU2039501A (en) 1999-10-15 2001-04-23 Rockefeller University, The System for rapid generation of recombinant baculovirus-based expression vectors for silkworm larvae
GB9929613D0 (en) * 1999-12-15 2000-02-09 Koninkl Philips Electronics Nv Manufacture of semiconductor material and devices using that material
SE0000055D0 (sv) * 2000-01-10 2000-01-10 Centaur Pharmaceuticals Inc Novel process
US6586207B2 (en) 2000-05-26 2003-07-01 California Institute Of Technology Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
GB0012997D0 (en) 2000-05-26 2000-07-19 Eurogene Limited Gene delivery
WO2002000216A1 (en) * 2000-06-28 2002-01-03 Teva Pharmaceutical Industries Ltd. Carvedilol
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
JP2002030098A (ja) 2000-07-17 2002-01-29 Institute Of Immunology Co Ltd バキュロウィルスの発芽ウイルスからウイルスエンベロープを回収する方法
AU2001273385B2 (en) 2000-09-08 2005-04-07 Gryphon Therapeutics, Inc. Polymer-modified synthetic proteins
EP2796546B1 (en) 2001-04-19 2017-08-09 The Scripps Research Institute Incorporation of unnatural amino acids
US6608196B2 (en) * 2001-05-03 2003-08-19 Galileo Pharmaceuticals, Inc. Process for solid supported synthesis of pyruvate-derived compounds
DE60228954D1 (en) * 2001-05-03 2008-10-30 Galileo Lab Inc Pyruvatderivate
GB0113657D0 (en) 2001-06-05 2001-07-25 Geneprot Inc Improved native chemical ligation with three or more components
US20030154058A1 (en) * 2001-06-11 2003-08-14 Keener Bryan F. Methods and systems for validating translated geometry
US20040138412A1 (en) 2001-09-07 2004-07-15 Paolo Botti Extended native chemical ligation
EP1434576A4 (en) * 2001-09-13 2006-03-29 Kenneth E Miller METHOD FOR RELIEVING PAIN
KR100948532B1 (ko) 2001-11-07 2010-03-23 넥타르 테라퓨틱스 분지형 중합체 및 그의 공액체
EP1456225A2 (en) 2001-11-14 2004-09-15 Geneprot, Inc. Extended native chemical ligation of three or more peptide fragments
MXPA04004809A (es) * 2001-11-20 2004-08-11 Pharmacia Corp Conjugados de hormona de crecimiento humana modificada quimicamente.
PT1578949E (pt) 2002-10-16 2009-07-14 Scripps Research Inst Incorporação específica do local de cetoaminoácidos em proteínas
US7642085B2 (en) 2002-12-22 2010-01-05 The Scripps Research Institute Protein arrays
AU2003300139B2 (en) * 2002-12-31 2008-08-28 Nektar Therapeutics Maleamic acid polymer derivatives and their bioconjugates
KR100940619B1 (ko) * 2003-02-07 2010-02-05 이난타 파마슈티칼스, 인코포레이티드 마크로사이클릭 씨형 간염 세린 단백효소 억제제
AU2004233083B2 (en) 2003-04-17 2010-09-16 The Scripps Research Institute Expanding the eukaryotic genetic code
EP1663302B1 (en) * 2003-09-03 2012-06-13 Alpharma, LLC Method for vaccination of poultry by bacteriophage lysate
MX2007007590A (es) 2004-12-22 2007-12-10 Ambrx Inc Composiciones que contienen, metodos que involucran y usos de aminoacidos no naturales y polipeptidos.
ATE542920T1 (de) * 2004-12-22 2012-02-15 Ambrx Inc Modifiziertes menschliches wachstumshormon
JP4478883B2 (ja) * 2005-03-25 2010-06-09 ヤマハ株式会社 音楽再生装置およびプログラム
DE102005036719A1 (de) * 2005-07-28 2007-02-01 Carl Zeiss Industrielle Messtechnik Gmbh Verfahren zum Korrigieren von Interpolationsfehlern einer Maschine, insbesondere eines Koordinatenmessgerätes
CN101400646A (zh) 2005-11-08 2009-04-01 Ambrx公司 用于修饰非天然氨基酸和非天然氨基酸多肽的促进剂
CN105384807A (zh) 2005-12-14 2016-03-09 Ambrx公司 含有非天然氨基酸和多肽的组合物、涉及非天然氨基酸和多肽的方法以及非天然氨基酸和多肽的用途
AU2006332809A1 (en) 2005-12-30 2007-07-12 Ambrx, Inc. Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
US7760037B2 (en) * 2007-03-28 2010-07-20 Intel Corporation Process, voltage, and temperature compensated clock generator
US20090113333A1 (en) 2007-10-26 2009-04-30 Palm, Inc. Extendable Toolbar for Navigation and Execution of Operational Functions

Also Published As

Publication number Publication date
AU2010226982A1 (en) 2010-10-28
IL220740A (en) 2017-10-31
US20080213840A1 (en) 2008-09-04
EP2399893A2 (en) 2011-12-28
SG158149A1 (en) 2010-01-29
US20060217532A1 (en) 2006-09-28
CA2927595C (en) 2023-01-31
IL183346A0 (en) 2007-09-20
CA3005835C (en) 2023-01-31
GB0713066D0 (en) 2007-08-15
IL227753A (en) 2017-10-31
EP1828224B1 (en) 2016-04-06
US7332571B2 (en) 2008-02-19
EP2399893A3 (en) 2012-08-08
US20060217289A1 (en) 2006-09-28
US20080153979A1 (en) 2008-06-26
US7385028B2 (en) 2008-06-10
US8008456B2 (en) 2011-08-30
JP5425398B2 (ja) 2014-02-26
US8809511B2 (en) 2014-08-19
KR20070100749A (ko) 2007-10-11
BRPI0516385B1 (pt) 2021-07-20
US20090123968A1 (en) 2009-05-14
BRPI0516385A (pt) 2007-11-27
IL183346A (en) 2014-06-30
DK1828224T3 (en) 2016-07-18
US20080177027A1 (en) 2008-07-24
CN104803865A (zh) 2015-07-29
US20080182969A1 (en) 2008-07-31
CA2927595A1 (en) 2006-06-29
US8846876B2 (en) 2014-09-30
US7638491B2 (en) 2009-12-29
US20090111147A1 (en) 2009-04-30
US20130030160A1 (en) 2013-01-31
NZ555308A (en) 2010-10-29
WO2006069246A3 (en) 2008-09-25
US8476411B2 (en) 2013-07-02
US20150094457A1 (en) 2015-04-02
CA2590590C (en) 2016-04-19
DK2399893T3 (en) 2018-10-08
WO2006069246A9 (en) 2006-08-31
US8367612B2 (en) 2013-02-05
EP1828224A2 (en) 2007-09-05
JP2008545371A (ja) 2008-12-18
CA3005835A1 (en) 2006-06-29
US20110124880A1 (en) 2011-05-26
WO2006069246A2 (en) 2006-06-29
GB2438982A (en) 2007-12-12
SG158186A1 (en) 2010-01-29
KR101423769B1 (ko) 2014-07-30
US20080177038A1 (en) 2008-07-24
US8048988B2 (en) 2011-11-01
US20080268519A1 (en) 2008-10-30
US8263740B2 (en) 2012-09-11
US7696312B2 (en) 2010-04-13
CA2590590A1 (en) 2006-06-29
US20110288279A1 (en) 2011-11-24
EP2399893B1 (en) 2018-08-15
US20080268518A1 (en) 2008-10-30
US7928163B2 (en) 2011-04-19
EP1828224A4 (en) 2009-02-25
US9637441B2 (en) 2017-05-02
US20080182968A1 (en) 2008-07-31
AU2010226982B2 (en) 2012-02-23
US20110118501A1 (en) 2011-05-19
US20110118451A1 (en) 2011-05-19
US20060194256A1 (en) 2006-08-31
IL227753A0 (en) 2013-09-30
US20100120686A1 (en) 2010-05-13
US8859802B2 (en) 2014-10-14
IL220740A0 (en) 2012-08-30
AU2005319125A1 (en) 2006-06-29
SG158148A1 (en) 2010-01-29
MX2007007590A (es) 2007-12-10
US8791231B2 (en) 2014-07-29

Similar Documents

Publication Publication Date Title
IL183346A0 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
IL209386A0 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
IL190748A0 (en) Methods and compositions comprising non-natural amino acids
IL187191A0 (en) Incorporation of non-naturally encoded amino acids into proteins
ZA200704925B (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
HRP20160455T1 (hr) Smjese polipeptida, sastavi koji ih sadrže i postupci za njihovu pripremu, te njihove primjene
ZA200703561B (en) Methods and compositions for improving recombinant protein production
IL179808A0 (en) Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP2102355A4 (en) PROTEINS AND PEPTIDES WITH EXTENDED ACTION AND METHODS OF PRODUCTION AND USE THEREOF
EP1824796A4 (en) PROTEIN SKELETONS AND USES THEREOF
EP1986674A4 (en) PROTEIN OR PEPTIDE COMPOSITIONS PROTEIN CONTAINING METHIONINE AND METHOD FOR MANUFACTURING AND USING SAME
PL1940240T3 (pl) Kompozycje izolatu białka i ich zastosowania
EP1843661A4 (en) COMPOSITIONS COMPRISING O-ACETYLSALICYL DERIVATIVES OF AMINO ACID AND AMINO ACIDS
EP1865953A4 (en) COMPOSITION OF N-PROPANOYL DERIVATIVES OF AMINO ACIDS, AMINO CARBOHYDRATES AND ITS DERIVATIVES
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
ZA200700359B (en) Biosynthetic polypeptides utilizing non-naturally encoded amino acids
EP1765374A4 (en) COMPOSITIONS, PROCESSES AND USES FOR A NEW FAMILY OF PEPTIDES
PL1890720T3 (pl) Kompozycje farmaceutyczne zawierające peptydy pochodzące z kazeiny i sposoby ich stosowania
EP1633851A4 (en) METHODS AND COMPOSITIONS FOR THE PRODUCTION OF AMINO ACIDS
PL1998790T3 (pl) Kompozycje zawierające peptydy z aminokwasami niewystępującymi w przyrodzie i sposoby stosowania
ZA200510463B (en) Methods and compositions for amino acid production
ZA200710374B (en) Pharmaceutical compositions comprising casein derived peptides and methods of use thereof
SG120237A1 (en) Non-essential amino acids containing pharmaceutical composition and uses thereof
GB0306845D0 (en) Method of comparing protein composition
IL222485A (en) Medical preparations that contain peptide-derived peptides and methods for their use